



November 11, 2011

## **pSivida Corp. to Hold Monday November 14 Conference Call to Discuss Complete Response Letter for ILUVIEN(R) for DME and pSivida's Product Pipeline**

WATERTOWN, Mass., Nov 11, 2011 (BUSINESS WIRE) --

pSivida Corp. (NASDAQ:PSDV, ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that it will host a live webcast and conference call Monday, November 14, 2011, at 9:00 am ET to discuss the receipt by its licensee Alimera Sciences, Inc. of a complete response letter from the U.S. Food and Drug Administration in response to the New Drug Application for ILUVIEN® for the treatment of diabetic macular edema associated with diabetic retinopathy announced earlier today.

"In addition to discussing the CRL, we will also discuss our product pipeline outside of ILUVIEN, including our other two clinical stage product candidates: one we are independently developing to treat uveitis affecting the posterior segment of the eye using the same insert as ILUVIEN and the other we are developing in collaboration with Pfizer to treat glaucoma and ocular hypertension. We also continue to advance our BioSilicon research and development," said Dr. Paul Ashton, Ph.D., President and CEO of pSivida. "Although we will not be due the \$25 million milestone payment for FDA approval of ILUVIEN, we continue to believe that our \$21.3 million of cash resources at September 30, 2011 is sufficient to support our current and planned operations into at least calendar year 2013."

The conference call may be accessed by dialing (866) 788-0538 from the U.S. and Canada, or (857) 350-1676 from international locations, passcode 53581980. The conference can also be accessed on the pSivida Corp. website at [www.psivida.com](http://www.psivida.com). A replay of the call will be available approximately two hours following the end of the call through November 21, 2011. The replay may be accessed by dialing (888) 286-8010 within the U.S. and Canada or (617) 801-6888 from international locations, passcode 70929780.

The conference call will be available via the Internet at [www.psivida.com](http://www.psivida.com) and will also be distributed through the Thomson StreetEvents Network. Individual investors can listen to the call via [www.earnings.com](http://www.earnings.com) and Institutional investors can access the call via [www.streetevents.com](http://www.streetevents.com). Listeners are encouraged to login at least 15 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software. The call will be archived and accessible on the Web site for approximately 30 days.

### **About pSivida Corp.**

pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert™ and BioSilicon™.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. The following are some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements: ability to obtain additional capital if needed; future losses; impairment of intangibles; fluctuations in the fair values of certain outstanding warrants; fluctuations in operating results; decline of royalty income from Bausch & Lomb; Alimera's ability to obtain regulatory approval of ILUVIEN for DME; Alimera's ability to successfully commercialize ILUVIEN for DME if approved; risk/benefit profile of ILUVIEN for DME; timeliness of approval, if any, of ILUVIEN for DME and any limitations on uses thereof; ability to complete clinical trials, reference data and obtain regulatory approval of other product candidates; ability to find partners to develop and market products; termination of license agreements; competition; market acceptance of products and product candidates; reduction in use of products as a result of future publications; ability to protect intellectual property or infringement of others' intellectual property; retention of key personnel; product liability; consolidation in the pharmaceutical and biotechnology industries; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; credit and financial market conditions; legislative or regulatory changes; volatility of stock price; possible dilution through exercise of outstanding warrants and stock options or future stock issuances; possible influence by Pfizer; ability to pay any registration

penalties; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

For more information on pSivida, visit [www.psivida.com](http://www.psivida.com).

SOURCE: pSivida Corp.

In US:

Beverly Jedynak, President, Martin E. Janis & Company, Inc.,

312-943-1123

[bjedynak@janispr.com](mailto:bjedynak@janispr.com)

or

In Australia:

Brian Leedman, Vice President, Investor Relations, pSivida Corp

+61 8 9227 8327

[brianl@psivida.com](mailto:brianl@psivida.com)